UNIBIOSCREEN’S Board Of Directors Appoints Pierre Hochuli As Chairman Of The Executive Committee

ANDERLECHT, Belgium, March 1, 2005 – UNIBIOSCREEN SA, a privately held Brussels-based cancer drug-discovery/development and contract research company, announced today the appointment of Pierre Hochuli as Chairman of the Executive Committee.

Pierre Hochuli, MBA, spent 23 years with Monsanto, where he most recently served as President International and Corporate Executive VP. At Monsanto, he was instrumental in developing the company’s top position in Ag Biotech and in pursuing the growth plan for its pharmaceutical business. He also was a member of the board of Industry Associations such as EuropaBio and US-China Business Council. Mr. Hochuli is Venture Partner of PolyTechnos, a German venture capital firm. During the last 4 years, Mr. Hochuli was on the Board of Directors of biopharmaceutical companies.

“Pierre has considerable analytical and strategic skills. His experience in the biopharmaceutical sector will be of high value to our company in guiding and optimizing the development of our most interesting products” said Dr. Robert Kiss, Unibioscreen’s CSO.

Unibioscreen is a drug discovery company focused on novel anti-cancer agents from natural origin (plants and marine invertebrates). Unibioscreen developed unique pharmacology and medicinal chemistry expertise to discover and develop anti-migratory, chemo-protective or anti-proliferative anti-tumour compounds.  The company’s portfolio includes several promising leads and patented families of compounds.

Unibioscreen also offers screening services to pharmaceutical/biotech companies active in cancer drug discovery. Unibioscreen’s customers utilize its integrated panel of in vitro and in vivo models to characterize mode of actions and drug efficacies of investigational compounds.

Unibioscreen was created in May 1999, as a spin-off from the Université Libre de Bruxelles (ULB).

For further information, please contact

Robert Kiss, CSO

robert.kiss@unibioscreen.com

Phone +32.529.59.75